| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Bacterial and fungal cell membranes. P-113 acts by disrupting bacterial membranes, leading to cell lysis. It also demonstrates potential in modulating immune responses, particularly by influencing macrophage activation and cytokine release.
|
|---|---|
| ln Vitro |
P-113 has a minimum inhibitory concentration (MIC) of 3.13 µg/mL against Candida albicans[1].
In vitro, P-113 shows antimicrobial activity against a broad spectrum of bacterial pathogens. It is active against clinically important microorganisms such as Pseudomonas spp., Staphylococcus spp., and C. albicans. The peptide acts by disrupting bacterial membranes, leading to cell lysis. The compound also modulates immune responses by influencing macrophage activation and cytokine release. |
| ln Vivo |
In vivo activity of P-113 has been studied in animal models of infection. As an antimicrobial peptide derived from a natural human salivary protein, it is expected to have favorable biocompatibility. Further details on in vivo efficacy are available in the primary research literature. The peptide shows potential for topical and systemic applications.
|
| Enzyme Assay |
Non-cell assays for P-113 focus on membrane disruption mechanisms rather than specific receptor binding. Artificial membrane models such as liposomes or planar lipid bilayers are used to assess membrane permeability changes. Fluorescent dye leakage assays are performed using calcein-loaded liposomes incubated with P-113 at concentrations of 0.1-100 μg/mL. Membrane disruption is measured by fluorescence increase over time.
|
| Cell Assay |
Cellular assays are performed using standard broth microdilution methods according to CLSI guidelines. Bacterial and fungal cultures are grown to mid-log phase and diluted to ~5×10⁵ CFU/mL. Two-fold serial dilutions of P-113 are prepared in 96-well plates. Microorganisms are added and incubated at 37°C for 18-24 hours. The MIC is determined as the lowest concentration with no visible growth. Eukaryotic cell cytotoxicity is evaluated using mammalian cell lines (e.g., HaCaT keratinocytes) with MTT assays.
|
| Animal Protocol |
In vivo efficacy studies are conducted in murine models of infection. P-113 is administered via topical, intraperitoneal, or intravenous routes at doses determined from pharmacokinetic studies. Efficacy endpoints include bacterial load (CFU/g tissue), survival, and histological analysis of infection sites. Immunomodulatory effects are assessed by measuring cytokine levels in serum and tissue.
|
| ADME/Pharmacokinetics |
Published pharmacokinetic data for P-113 are limited. As a peptide (molecular weight: 1563.81), it is expected to have limited oral bioavailability and is likely administered parenterally or topically. The peptide is soluble in water and DMSO. Further studies on half-life, clearance, and metabolism would be required for therapeutic development.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicology data for P-113 are limited to research use. As a peptide derived from a human salivary protein, it is expected to have favorable biocompatibility. No significant toxicity has been reported at effective concentrations. Standard safety pharmacology studies would be required for therapeutic development. The compound is for research use only.
|
| References | |
| Additional Infomation |
P-113 is an antimicrobial peptide derived from the human salivary protein histatin 5. It is a 12-amino acid peptide with the sequence AKRHHGYKRKFH. The peptide exhibits broad-spectrum antimicrobial activity and modulates immune responses. P-113 is a promising candidate for the development of new antimicrobial therapies, particularly against drug-resistant pathogens. It is not approved for clinical use and is available for research purposes only.
|
| Molecular Formula |
C71H110N28O13
|
|---|---|
| Molecular Weight |
1563.84
|
| Exact Mass |
1562.88
|
| CAS # |
190673-58-6
|
| PubChem CID |
16158146
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.695
|
| LogP |
-6.81
|
| Hydrogen Bond Donor Count |
26
|
| Hydrogen Bond Acceptor Count |
22
|
| Rotatable Bond Count |
55
|
| Heavy Atom Count |
112
|
| Complexity |
3000
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC2=CNC=N2)C(=O)NCC(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N)N
|
| InChi Key |
UIBPZXXSPHGPDS-GUBPWTFESA-N
|
| InChi Code |
InChI=1S/C71H110N28O13/c1-41(75)60(103)91-48(15-5-8-24-72)62(105)94-52(19-12-28-85-71(79)80)66(109)99-57(33-46-36-83-40-89-46)69(112)98-56(32-45-35-82-39-88-45)61(104)86-37-58(101)90-54(30-43-20-22-47(100)23-21-43)67(110)95-49(16-6-9-25-73)63(106)93-51(18-11-27-84-70(77)78)64(107)92-50(17-7-10-26-74)65(108)97-55(29-42-13-3-2-4-14-42)68(111)96-53(59(76)102)31-44-34-81-38-87-44/h2-4,13-14,20-23,34-36,38-41,48-57,100H,5-12,15-19,24-33,37,72-75H2,1H3,(H2,76,102)(H,81,87)(H,82,88)(H,83,89)(H,86,104)(H,90,101)(H,91,103)(H,92,107)(H,93,106)(H,94,105)(H,95,110)(H,96,111)(H,97,108)(H,98,112)(H,99,109)(H4,77,78,84)(H4,79,80,85)/t41-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-/m0/s1
|
| Chemical Name |
(2S)-6-amino-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-amino-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-2-[[(2S)-2-aminopropanoyl]amino]hexanamide
|
| Synonyms |
P113; P 113; P-113
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~63.95 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (63.95 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6395 mL | 3.1973 mL | 6.3945 mL | |
| 5 mM | 0.1279 mL | 0.6395 mL | 1.2789 mL | |
| 10 mM | 0.0639 mL | 0.3197 mL | 0.6395 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
